New Hybrid Virus plus RSV Vax as Moderna’s New Money Maker

New Hybrid Virus Discovered as Flu And RSV Fuse Into Single Pathogen

Actually they should have said New Hybrid Virus created in Lab as Flu And RSV Fuse Into Single Pathogen

It was discovered during a lab-based experiment designed to analyze interactions between viruses during infection to better understand clinical outcomes, pathogen behavior, and transmission.

Human lung cells were exposed to both viruses, as well as each virus individually as a control group. An assortment of microscopy techniques then revealed filamentous structures consistent with a hybrid of both virus particles

When these two viruses join forces, influenza A appears to infect a higher number and broader range of human cells. The influenza A particles were found to evade the immune system by displaying the RSV surface proteins, giving the virus a survival advantage.

The hybrid also spread into cells that lacked influenza receptors, which could allow influenza A to move further down the respiratory tract into the lungs and lead to more severe infections.

Hearing a lot about RSV so did a quick search

Oooh, Tripledemic, thats catchy

Lets stick with RSV.  Its been around for only 60+ years.  Mainly affects children and immunocompromised adults like the elderly.  Where did it come from?

Here is a bit of history from one of my old posts

According to a BMJ rapid response dated 26 August 2012 (Eradication of polio by vaccination Part 3),

https://www.bmj.com/content/344/bmj.e2398/rr/599724

Morris et al. (1956) isolated and identified monkey cytopathogenic agent that produced acute respiratory illness in chimpanzees at the Walter Reed Army Institute of Research and named it chimpanzee coryza virus (CCV).   

Chanock et al.(1957) pointed out the association of a new type of cytopathogenic myxovirus with infantile croup. Chanock and Finberg (1957) reported on two isolations of similar agents from infants with severe lower respiratory illness (bronchopneumonia, bronchiolitis and laryngotracheobronchitis).

The two viruses were indistinguishable from an agent associated with the outbreak of coryza in chimpanzees (Chimpanzee coryza agent or CCA virus, studied by Morris et al. (1956).

A person working with the infected chimpanzees (CCA virus of Morris et al. as above) subsequently experienced respiratory infection with a rise in CCA antibodies during convalescence.

A new name was proposed for this agent:”respiratory syncytial virus” (RSV). The original name “chimpanzee coryza virus” disappeared from medical literature.

In Australia, Lewis et al. (1961) isolated further viral specimens identical with CCA. They wrote, “Prior to July 1960, the influenza and parainfluenza viruses predominated in infant epidemic respiratory infections.

In July 1961 the pattern changed abruptly with sudden increases in bronchiolitis and bronchitis, infrequent before. 58% were under 12 months, and patients under 4 years predominated. Infants with bronchiolitis and severe bronchitis yielded RCA not previously isolated. Deaths have occurred.”

1967-infants and toddlers immunized with a formalin-inactivated vaccineagainst respiratory syncytial virus(RSV) experienced an enhanced form of RSV disease characterized by high fever, bronchopneumonia, and wheezing when they became infected with wild-type virus in the community

Levy et al. (1997) ascertained that respiratory syncytial virus (RSV) became the most prevalent cause of lower respiratory tract infections (LRTI) in infants and young children. “Infections with RSV are a major health problem during early childhood and primary RSV infections occur most often between the ages of 6 weeks and 2 years.

Approximately one half of all infants became infected with RSV during the first year of life…In the US each year approximstely100,000 children are hospitalised at an estimated cost of $300 million. More than half of those admitted for RSV bronchiolitis are between 1 and 3 months of age”

To quote Simoes (1999), “Since it [RSV] was identified as the agents causing chimpanzee coryza in 1956, and after its subsequent isolation from children with pneumonary disease in Baltimore,USA, respiratory syncytial virus (RSV) had been described as the single most important virus causing acute respiratory tract infections in children.

The WHO estimates that of the 12.2 million annual deaths in children under 5 years, a third are due to acute infections of the lower respiratory tract. Streptococcus pneumoniae, Haemophilus influenzae, and RSV are the predominant pathogens…vaccinated children were not protected from subsequent RSV infection.

Furthermore, RSV-naïve infants who received formalin-inactivated RSV vaccine, and who were naturally infected with RSV later, developed more severe disease in the lower respiratory tract than a control group immunized with a trivalent parainfluenza vaccine.”…

Data from ten developing countries with intense polio vaccination showed RSV the most frequent cause of lower respiratory tract infections (70% of all cases).”

The yearly cost of bronchiolitis in the USA goes into billions.

Johnson et al. (2014) write, “Respiratory syncytial virus (RSV) is a major cause of disease and hospitalisations in infants and young children worldwide, resulting in more than 3.4 million hospitalisations and more than 200,000 deaths globally.

Medically attended RSV pediatric disease in the USA exceeds $1 billion in direct medical costs annually.

RSV infections also cause significant mortality and morbidity in the elderly and other high risk adults.”…

“Clinical trials of a formalin-inactivated RSV vaccine (F1-RSV) in young infants did not protect against infection, but increased disease severity…

Progress has been hampered by limited immunogenicity, induction of Th2-biased immunity or unacceptable levels of adverse events. Natural RSV infection does not induce long-term protection, possibly due to the ability of RSV to suppress or evade host immunity.”

But never fear, Moderna coming to the rescue with new RSV vaccine. A whopping trial size of 7000 participants designed to ensure safety signals of events less frequent than 1/1000 will not be picked up

https://clinicaltrials.gov/ct2/show/NCT05572658

You think they will do proper bio distribution studies and check troponin levels of all participants? Don’t hold your breath

In any event, despite there being no emergency declared-yet, the vaccine is expected by next fall

https://edition.cnn.com/2022/10/31/health/rsv-vaccines-therapies/index.html

Maybe it works against the New Hybrid (RSV + Influenza) Virus if it “escapes” from the lab

In any event Moloch will be fed